ICON’s Ioannis Katsoulis, Axel Svedbom, Larushka Mellor and Örjan Åkerborg consider trends and strategies to drive uptake of biosimilars in the UK - Magazine Article - PharmaTimes
by John Pinching
www.pharmatimes.com/magazine/2019/october_2019/embracing_biosimilarsAmid the chaos of Brexit, pioneering clinical research continues defiantly, plotting its way through the complexity of disease and providing patients with the currencies of hope, transformation and reinvention. - Magazine Article - PharmaTimes
by John Pinching
www.pharmatimes.com/magazine/2019/october_2019/trial_blazersHow CSOs can look to the future to forge successful relationships with pharma - Magazine Article - PharmaTimes
by John Pinching
www.pharmatimes.com/magazine/2018/december_2018/tomorrow_peopleThe future of AI in pharma and wider healthcare is unfolding right now – never has the crystal ball of science found itself so resolutely in the present. If we dare to glance at the horizon, however, we will see the dreamscape of an
by John Pinching
www.pharmatimes.com/magazine/2019/may/a_new_horizonAn exciting, futuristic chapter for clinical trials has opened in which participant engagementwill flourish, expansive data will navigate the maze of disease and digital technology will take pharma and patients to previously unexplored dimensions.
by John Pinching
www.pharmatimes.com/magazine/2019/march/resistance_is_futileIn its finest hours, the bond between patients and pharma can move mountains, defy disease and change the course of history - Magazine Article - PharmaTimes
by John Pinching
www.pharmatimes.com/magazine/2019/april/in_sickness_and_in_healthTo understand the full scope of a condition, pharma needs to appreciate the full tapestry of the patient experience. The challenge for industry in the realm of rare diseases, however, is to meaningfully engage with patients and convince them that
by John Pinching
www.pharmatimes.com/magazine/2019/september_2019/its_a_small_worldSales in pharma is a frequently changing canvass. Its leveraging of technology has triggered new, bold approaches, while also upholding a fine tradition of individuality among its multifarious and talented workforce. Finding the most compelling mix
by John Pinching
www.pharmatimes.com/magazine/2019/june_2019/flight_of_the_navigatorsSuccessful treatment development relationships rely on the ability of contract research organisations to bring their skills to the table – and pharma’s willingness to let that happen - Magazine Article - PharmaTimes
by John Pinching
www.pharmatimes.com/magazine/2018/november_2018/as_the_cro_fliesAn all-encompassing digital era has opened unique opportunities for industry to engage with patients meaningfully, while also creating a modernised healthcare landscape which yields trust and cooperation. For the most impactful communicators the
by John Pinching
www.pharmatimes.com/magazine/2019/januaryfebruary_2019/centre_of_the_pharmaverse
